Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 6,770 matching trials from the live ClinicalTrials.gov search.

Filters: Bethesda, Maryland Clear all

Conditions: HIV Infections
Interventions: Daclizumab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertension, Portal
Interventions: GR-MD-02, Placebo; Drug
Lead sponsor: Galectin Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 46
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 39 more

Conditions: Large B Cell Lymphoma
Interventions: rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide, filgrastim, pegfilgrastim; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2021
U.S. locations: 47
States / cities: La Jolla, California • Mountain View, California • Palo Alto, California + 38 more

Conditions: Atherosclerosis
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years to 100 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Acute Coronary Syndrome
Interventions: Milvexian, Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 14,194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 162
States / cities: Alexander City, Alabama • Birmingham, Alabama • Mobile, Alabama + 141 more

Conditions: Epstein-Barr Virus Infections, Lymphoma, Lymphoproliferative Disorder, Disorders, Lymphoproliferative
Interventions: Nivolumab; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Asthma
Interventions: Dose 4 QD, Dose 3 QD, placebo, Dose 2 QD, Dose 1 BD; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 9
States / cities: Cypress, California • Huntington Beach, California • Bethesda, Maryland + 6 more

Conditions: Cancer, Inflammatory Disease, Vascular Diseases, Metabolic Bone Disease
Interventions: PHOTON COUNTING CT Scanner; Device
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: B Cell Lymphoma, Follicular Lymphoma, Neoplasm
Interventions: Id-KLH Vaccine, QS-21 (Stimulation-QS-21) Drug; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Primary Ovarian Insufficiency, Azoospermia, Oligospermia
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Bethesda, Maryland • Rockville, Maryland

Conditions: Myeloma-Multiple, Myeloma, Plasma-Cell
Interventions: Cyclophosphamide, Fludarabine, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 73 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Idiopathic CD4+ T-Lymphocytopenia
Interventions: CYT107; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA), Severe Aplastic Anemia (SAA)
Interventions: Umbilical Cord Blood; Biological
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 4 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostatic Neoplasms, Prostate Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Blindness
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Granulomatous Disease
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Solid Tumors
Interventions: Bevacizumab, Dasatinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Critical Illness
Interventions: Oral Care; Behavioral
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland • Fairfax, Virginia + 1 more

Conditions: Rhinitis, Allergic, Seasonal
Interventions: Ciclesonide HFA, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 31
States / cities: Mission Viejo, California • Orange, California • San Diego, California + 28 more

Conditions: Kidney Transplantation
Interventions: Allogeneic Bone Marrow, Anti-Thymocyte Globulin (Sangstat) & Sirolimus (Wyeth-Ay; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 12 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Core Binding Factor Alpha Subunits, Hematologic Neoplasms, Leukemia, Lymphoma
Interventions: Cyclophosphamide, Busulfan, Fludarabine, Total Body Irradiation, Hematopoietic stem cells, Tacrolimus, Mycophenolate Mofetil; Drug · Radiation · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 4 Years to 70 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Overweight, Eating Behavior, Binge Eating
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 13 Years to 17 Years
Enrollment: 301 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Brain and Central Nervous System Tumors
Interventions: gefitinib; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more

Conditions: Non Small Cell Lung Cancer
Interventions: PF-02341066, PF-00299804; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 9
States / cities: Aurora, Colorado • Bethesda, Maryland • Boston, Massachusetts

Search by objective public record fields.

Daclizumab to Treat HIV-Infected Patients

Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Identification of Genes Expressed in Atherosclerotic Plaque

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

Efficacy and Safety Study in Subjects With Asthma

Translational Development of Photon-counting CT Imaging

Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype

Identifying Genome Variants in Non-Obstructive Azoospermia (NOA) or Primary Ovarian Insufficiency (POI)

T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma

Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)

Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelodysplastic Syndrome

Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy

Enhanced Tactile Memory in the Blind

Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995

Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors

Oral Care to Reduce Mouth and Throat Infections in Critically Ill Patients

Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)

Evaluating the Use of Thymoglobulin, Sirolimus, and Donor Bone Marrow With Kidney Transplantation Patients

Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers

Eating Behavior in Adolescents

Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer